Loading
The European oncology society's 2024 guideline for breast cancer that has not spread, covering diagnosis, surgery, radiotherapy, drug treatment before and after surgery, and follow-up; the reference standard for European and UK care of early triple-negative disease.
ESMO Clinical Practice Guideline for early breast cancer, published in Annals of Oncology in 2024 by Loibl, André, Bachelot, Barrios and colleagues for the ESMO Guidelines Committee. Europe PMC indexes no abstract for this article, so OnCo carries no figures from it; the guideline itself is open on the ESMO website. For triple-negative disease it sets out neoadjuvant chemo-immunotherapy on the KEYNOTE-522 model for stage II to III tumours, platinum in the neoadjuvant regimen, adjuvant olaparib for germline BRCA carriers with residual disease (OlympiA) and capecitabine for residual disease without a BRCA variant (CREATE-X).
This is the European standard the UK page for triple-negative breast cancer is compared against; NICE guidance covers the same ground with a narrower set of funded drugs.
Shares Sibylle Loibl, KEYNOTE-522, Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Sibylle Loibl, Annals of Oncology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares ESMO Clinical Practice Guidelines & MCBS, European Society for Medical Oncology (ESMO), Annals of Oncology, HER2-positive breast cancer and the tag tnbc-evidence.
Shares OlympiA, KEYNOTE-522, Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares European Society for Medical Oncology (ESMO), Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares OlympiA, Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.